Dietary essential amino acids for the treatment of heart failure with reduced ejection fraction

Maurizio Ragni1, Carolina Magdalen Greco2,3, Arianna Felicetta2, Shuxun Vincent Ren4, Paolo Kunderfranco2, Chiara Ruocco1, Pier Luigi Carullo2,5, Veronica Larcher2, Laura Tedesco1, Ilenia Severi6, Antonio Giordano6, Saverio Cinti6, Alessandra Valerio7, Haipeng Sun4†, Yibin Wang4, Chen Gao4, Gianluigi Condorelli2,3,4, and Enzo Nisoli1*

1Center for Study and Research on Obesity, Department of Medical Biotechnology and Translational Medicine, University of Milan, Via Vanvitelli 32, Milan 20129, Italy; 2Department of Cardiovascular Medicine, Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano (Milan), Italy; 3Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele (Milan), Italy; 4Departments of Anesthesiology, Medicine and Physiology, David Geffen School of Medicine at University of California, Los Angeles, 90095 CA, United States; 5National Research Council of Italy, Institute of Genetics and Biomedical Research, Milan 20090, Italy; 6Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona 60126, Italy; and 7Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy

Received 24 June 2022; revised 5 November 2022; editorial decision 11 November 2022; online publish-ahead-of-print 10 January 2023

Aims
Heart failure with reduced ejection fraction (HFrEF) is a leading cause of mortality worldwide, requiring novel therapeutic and lifestyle interventions. Metabolic alterations and energy production deficit are hallmarks and thereby promising therapeutic targets for this complex clinical syndrome. We aim to study the molecular mechanisms and effects on cardiac function in rodents with HFrEF of a designer diet in which free essential amino acids—in specifically designed percentages—substituted for protein.

Methods and results
Wild-type mice were subjected to transverse aortic constriction (TAC) to induce left ventricle (LV) pressure overload or sham surgery. Whole-body glucose homeostasis was studied with glucose tolerance test, while myocardial dysfunction and fibrosis were measured with echocardiogram and histological analysis. Mitochondrial bioenergetics and morphology were investigated with oxygen consumption rate measurement and electron microscopy evaluation. Circulating and cardiac non-targeted metabolite profiles were analyzed by ultrahigh performance liquid chromatography-tandem mass spectroscopy, while RNA-sequencing was used to identify signalling pathways mainly affected. The amino acid-substituted diet shows remarkable preventive and therapeutic effects. This dietary approach corrects the whole-body glucose metabolism and restores the unbalanced metabolic substrate usage—by improving mitochondrial fuel oxidation—in the failing heart. In particular, biochemical, molecular, and genetic approaches suggest that renormalization of branched-chain amino acid oxidation in cardiac tissue, which is suppressed in HFrEF, plays a relevant role. Beyond the changes of systemic metabolism, cell-autonomous processes may explain at least in part the diet’s cardioprotective impact.

Conclusion
Collectively, these results suggest that manipulation of dietary amino acids, and especially essential amino acids, is a potential adjuvant therapeutic strategy to treat systolic dysfunction and HFrEF in humans.

* Corresponding author. Tel: +39 (02) 50316956, Fax: +39 02 50317118, E-mail: enzo.nisoli@unimi.it
† Present address: Department of Pathophysiology, Hongqiao International Institute of Medicine, Tongren Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University, School of Medicine, Shanghai, 200240, China.
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
1. Introduction

Heart failure (HF) is a major cause of hospitalization and mortality, imposing substantial public health and economic burden worldwide.1,2 The use of β-adrenergic receptor and renin-angiotensin antagonists, aldosterone receptor antagonists, and the recent angiotensin receptor neprilysin inhibitor has improved morbidity and mortality rates. Sodium-glucose cotransporter 2 inhibitors have added novel cardioprotective therapeutic approaches, practical to ameliorate cardiac dysfunction and increase exercise capacity in patients with HF with reduced ejection fraction (HFrEF), and to reduce at least hospitalization in patients with HF with preserved ejection fraction (HFpEF), for whom there are so far no evidence-based therapies.3 However, both HFrEF and HFpEF patients still have poor long-term outcomes,4 highlighting the need for novel therapeutic and lifestyle interventions.

HFrEF is associated with an imbalance of energy metabolism, characterized by perturbations in mitochondrial function, redox reactions,5 adenosine triphosphate synthesis,6 and substrate utilization (i.e. reduced fatty acid and pyruvate oxidation and increased glucose utilization).7,8 More recent studies have identified the critical role of amino acid metabolism perturbation in the pathogenesis of HFrEF.9 They suggest how restoring the mitochondrial branched-chain amino acid (BCAA) oxidation—characteristically damaged in failing heart—improves cardiac metabolic flexibility and alleviates systolic dysfunction in HFrEF.10

Several dietary interventions have been proposed as a valuable strategy to improve whole-body and cardiac energy metabolism and treat clinical conditions caused by impaired energy production. In contrast, no data on diet ability to improve BCAA oxidation have been reported yet. Supplementation of essential amino acids (EAs) is beneficial for energy disorders such as sarcopenia, liver and kidney diseases, obesity, and type 2 diabetes.11,12 Additionally, we previously found that the EAA supplementation extends survival in mice, mainly by promoting mitochondrial biogenesis, redox balance, and metabolic fitness in muscle and cardiac tissue.13 Thus, it is plausible that specific nutritional approaches might advantage the HFrEF patients at least at the energy production level.14,15

Driven by this speculation, we examined whether consumption of an EAA-enriched diet attenuated systolic dysfunction in transverse aortic constriction (TAC)-induced left ventricle (LV) pressure overload, a mouse model of HFrEF. Here, we show that a customized diet, in which a precise formula of EAAs substitutes for protein content—without changing calorie amount and macronutrient percentage—exerts remarkable preventive and therapeutic anti-HFrEF effects in mice. These effects are partially mediated through improved energy metabolism, promoting myocardial bioenergetics, efficient substrate utilization, and reduced fibrosis in the heart. These results suggest a rationale for investigating the effect of our amino acid-substituted diet in humans with HFrEF.
2. Methods

2.1 Animal models, diets, and ethical considerations

All procedures involving animal use were conducted in accordance with the European Community Guidelines (Directive 2010/63/EU) and those of the Italian Ministry of Health (Legislative Decree No. 26/2014), compiled with the National Animal Protection Guidelines, and were approved by the Institutional Animal Ethical Committee. Experiments with 2C-type serine-threonine protein phosphatase knockout mice (PP2Cm−/−) were approved by UCL IACUC in compliance of the US regulations and guidelines. Mice were housed in a temperature and humidity controlled facility with 12 h light/dark cycle and ad libitum access to food and water. Male C57BL/6N mice (8-weeks-old), from Charles River (Calco, Italy) or PP2Cm−/− mice16 were weight-matched and fed ad libitum for different periods of time with normal chow diet (CD: V1534-300, Ssniff Spezialdiäten GmbH, Soest, Germany). Mice were then fed with the following experimental diets before (preventive protocol) or after (therapeutic protocol) surgical pressure overload induction (see also the Results section, Figure 1A, and Supplementary material online, Figure S3A for explanations): control SFA diet; 20% Kcal from protein—namely casein, 70% from carbohydrate, and 10% from fat, half of which was oflard (D12450H). SFA-EAA diet: isocaloric, isoplastic, and isonitrogenous with SFA diet except for casein content, which was almost entirely (93.5%) replaced by a defined mixture of free EAAs (D14032501). Control SFA-CAA diet: isocaloric, isoplastic, and isonitrogenous with SFA in which casein was substituted with free amino acids designed on the amino acid profile of casein (A17092801) (see Supplementary material online, Table S1). All diets were from Research Diets Inc. (Brogdata, Gentofte, Denmark). Body weight and food intake were recorded twice a week in mice housed individually. Mice used have a C57BL/6N background, that does not exhibit defects of insulin release and mitochondrial dysfunction relative to C57BL/6 mice.17 At the end of the experimental procedures, euthanasia was performed by cervical dislocation while the mice were under a surgical plane of anaesthesia; tissue samples for molecular analysis were snap-frozen in liquid nitrogen and prepared as described below.

2.2 Transverse aortic constriction

Mice were anaesthetized with a single intraperitoneal injection of a mixture of ketamine (100 mg/kg), xylazine (5 mg/kg), and morphine (2.5 mg/kg), in accordance with the European Community Guidelines (see above). Anaesthetized mice were closely monitored during the procedure to assure that they were maintained in the proper anaesthetic plane. In particular, the anaesthetic efficacy was assessed by pinching the tail of the animal while monitoring body temperature and respiratory rate. Any reaction of the animal, hypothermia or increase in respiratory rate indicated that anaesthesia was too light and that additional anaesthetic should be given. TAC surgery was adapted from Rockman et al.18 Briefly, anaesthetized mice were placed in a supine position, the chest was shaved using a chemical hair remover, and the aortic arch was exposed through the first intercostal space. A 8–0 Prolene suture was tightened along with the needle and secured with a second knot. The needle was removed to create a lumen with a fixed stenotic diameter. Two-dimensional cine loops with frame rates of 200 frames per second in long- and short-axis views of the LVs were recorded. End-diastolic (d) and end-systolic (s) intraventricular septum (IVSTd, IVSTS), posterior wall thickness (PWTd, PWTs) and LV internal diameters (LVEDd, LVEDs) were measured. Percentage fractional shortening (% FS) and relative ejection fraction (% EF) were calculated using standard formulas: % FS = [(LVEDd–LVEDs)/LVEDd] × 100, % EF = [(LV ESP – LVEDV)/LVEDV] × 100.

2.3 Echocardiography

Echocardiography was performed on a Vevo 2100 (VisualSonics) system equipped with an M5505S probe ‘high frame’ scan head. Anaesthesia was induced with 3% isoflurane and maintained with a flow 1.0% isoflurane during constant monitoring of temperature, respiration rate, and ECG while maintaining heart rate at 450–550 beats per min. Two-dimensional cine loops with frame rates of 200 frames per second in long- and short-axis views of the LVs were recorded. End-diastolic (d) and end-systolic (s) intraventricular septum (IVSTd, IVSTS), posterior wall thickness (PWTd, PWTs) and LV internal diameters (LVEDd, LVEDs) were measured. Percentage fractional shortening (% FS) and relative ejection fraction (% EF) were calculated using standard formulas: % FS = [(LVEDd–LVEDs)/LVEDd] × 100, % EF = [(LV ESP – LVEDV)/LVEDV] × 100.

2.4 Immunoblot analysis

Protein extracts were obtained from tissues using T-PER Mammalian Protein Extraction Reagent (Pierce, Euroclone, Milan, Italy) as indicated by the manufacturer, in the presence of a cocktail of protease and phosphatase inhibitors (Sigma-Aldrich, Milan, Italy). Concentration of proteins was determined using BCA Protein Assay Reagent (Euroclone, Milan, Italy). Fifteen to twenty micrograms of proteins were separated on a 4–12% SDS-PAGE gel and transferred to PVDF membranes (Bio-Rad Laboratories, Milan, Italy). Membranes where then incubated with the primary antibodies and detection was performed using horseradish peroxidase conjugated anti-rabbit or anti-mouse immunoglobulin for 1 h at room temperature. Image acquisition was performed using SuperSignal Substrate (Pierce) and analyzed using ImageQuant TL software. For detection of phosphoproteins, filters were stripped with Strip Blot (Euroclone, Milan, Italy) and further used for the visualization of total proteins. Primary antibodies (each at 1:1 000 dilution) are listed in Supplementary material online, Table S2.

2.5 Insulin receptor substrate pan-tyrosine phosphorylation

Pan-tyrosine phosphorylation of insulin receptor substrate (IRS) was determined using PathScan Sandwich ELISA kits (Cell Signaling Technology) according to the manufacturer’s instructions.

2.6 Histology

Hearts were fixed in 10% buffered formalin and embedded in paraffin. Histology and immunostaining were performed on 5 μm-thick paraffin sections. Fibrosis was quantified using the Trichrome Stain (Masson) Kit (Sigma, HT15). Quantification of the fibrotic area was performed with ImageJ. After deparaffinization, tissue sections were incubated with an anti-wheat germ agglutinin (anti-WGA, Sigma-Aldrich) antibody, which marks fibrotic tissue in comparable quality as the established picrosirius red (SR) staining. Images were acquired with an SP8II Imaging system, and the cardiomyocyte cross-area sectional area was quantified with ImageJ.

2.7 Electron microscopy

Hearts from perfused mice were fixed in 2.5% glutaraldehyde and 2% formaldehyde in 0.1 M phosphate buffer over night at 4°C, post-fixed in 1% osmium tetroxide, dehydrated in acetone, and embedded in epoxy resin (all from Electron Microscopy Science, Società Italiana Chimici, Rome, Italy). Semi-thin sections (2 μm) were stained with toluidine blue. Thin sections obtained with an MT-X ultratome (RCM, Tucson, AZ, USA) were mounted on copper grids, stained with lead citrate and examined with a EM208 transmission electron microscope (Philips, Eindhoven, The Netherlands). Mean mitochondrial area, mitochondria density (number of mitochondria/area expressed in μm², normalized in 10 μm²) and number of mitochondria cristae (number of cristae/mitochondria area, normalized in 1 μm²) were determined by ImageJ.
2.8 Isolation of mitochondria and oxygen consumption measurement

Mitochondria from LV were isolated as described with some modifications. Briefly, LVs were excised, minced with scissors in 10 mM PBS-EDTA, and spun down. Supernatant was discarded, tissue pellet were resuspended in Trypsin-EDTA (Sigma-Aldrich) and incubated for 10 min on ice. Trypsin inhibitor (Sigma-Aldrich) was then added and the mixture was briefly spunned. Supernatant was removed and pellet was homogenized with a glass Potter Elvehjem teflon pestle in 0.3 M sucrose, 10 mM Na-Hepes, 0.2 mM EDTA, 1 mM EGTA, 0.1% bovine serum albumin, pH 7.2, and centrifuged at 600 g for 10 min at 4°C to spin down nuclear fraction. Supernatant was then collected and centrifuged again at 8 500 g.
for 10 min at 4°C. Pellet was washed with homogenization buffer, briefly re-centrifuged at 14,000 g for 5 min at 4°C and resuspended in a small volume of homogenization buffer. Mitochondrial oxygen consumption rate (OCR) was measured in a gas-tight vessel equipped with a Clark-type oxygen electrode (Rank Brothers Ltd., Cambridge, UK) at 30°C. Mitochondria were incubated in respiration medium (0.25 M Sucrose, 20 mM Na-Hepes, 0.4 mM EGTA, 3 mM MgCl2, 5 mM KH2PO4, 0.1% bovine serum albumin pH 7.2). Glucose- or fatty acid oxidation-dependent OCRs were measured in presence of pyruvate or palmitoyl-carnitine, respectively. The following substrates were used in sequence: 2.5 mM malate, 5 mM pyruvate (or 40 μM palmitoyl-CoA plus 2.5 mM carnitine), 100 μM ADP, and 0.01 mg/mL oligomycin (all from Sigma-Aldrich). ADP-stimulated oxygen consumption was used to calculate state 3 (coupled) respiration, and OCR after oligomycin addition was used to measure uncoupled respiration. Carboxyl cyanide-4-trifluoromethoxy phenylhydrazone (FCCP; Sigma-Aldrich) was subsequently added (500 nM) in the presence of oligomycin to obtain the maximal respiration rate. At the end of the measures, mitochondrial suspension was recovered and OCRs were then normalized to mitochondrial protein amount.

2.9 Metabolomics analysis
Non-targeted metabolite profiling, peak identification, and curration was performed by Metabolon (Durham, NC, USA). Samples were prepared using the automated MicroLab STAR® system from Hamilton Company in the presence of several recovery standards for QC purposes. Biochemicals were extracted and analyzed by ultrahigh performance liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS) in four ways: (i) acidic positive ion conditions (water and methanol), optimized for hydrophilic compounds; (ii) acidic positive ion conditions (water, methanol and acetonitrile), optimized for hydrophobic compounds; (iii) basic negative ion conditions; (iv) negative ionization. Raw data were extracted, peak-identified and QC processed using Metabolon’s hardware and software. Metabolites were identified by comparison to a library of purified standards with retention time/index, mass to charge ratio (m/z) and chromatographic data (MS/MS spectral data). Peaks were quantified using area-under-the-curve and normalized by amount of starting material (tissue).

2.10 RNA and DNA purification, gene expression, and mtDNA analysis by qPCR
Total RNA was isolated from LV samples using RNeasy Mini Kit (Qiagen) and treated with DNase according to the manufacturer’s protocol. cDNA was synthesized using an iScript cDNA Synthesis Kit (Bio-Rad Laboratories), and amplified by real-time quantitative PCR with iTaq Universal SYBR Green Supermix (Bio-Rad Laboratories). and amplified by real-time quantitative PCR with iTaq Universal SYBR Green Supermix (Bio-Rad Laboratories). for complete Claycomb medium supplemented with 10% fetal bovine serum (FBS), 0.1 mM norepinephrine, 100 U/ml penicillin/streptomycin, 2 mM L-glutamine in gelatin/fibronectin-coated flasks (all supplements from Sigma-Aldrich) at 37°C, 5% CO2. Although HL-1 cells are not ideal for studying cardiomycocytes metabolism, they are, however, widely used to study cardiomycocytes hypertrophy in vitro.24 Endothelin-1 (ET-1) (100 nM in DMSO) (Sigma-Aldrich) was added to cells (80–90% confluent) that were previously deprived for 48 hr of norepinephrine and then serum-starved overnight. For EAA supplementation, HL-1 cells were treated with vehicle or ET-1 as described above or supplemented with an essential amino acid mixture (EAAm) alone or in combination with ET-1 in Claycomb medium without FBS and norepinephrine. The mixture reproduces the stoichiometric ratio of the EAAm in the SFA-EAA defined diet, which, in turn, is based on the blend of AAs that has been previously shown, when supplemented with drinking water, to extend the average life span in mice.11 After 24 h, cells were harvested for analysis.

2.11 RNA-sequencing and data analysis
RNA from two biological replicates was isolated using the RNaseasy Mini Kit (Qiagen) and treated with DNase according to the manufacturer protocol. Total RNA quality was evaluated using LabChip GXTouch HT with HT DNA 5 K/RNA/CZE LabChip (Perkin Elmer) according to the manufacturer’s instructions. RNA-Seq libraries were created using the TruSeq Stranded mRNA Sample Prep Kit (Illumina, San Diego, USA) with 96 dual indexes, starting from 400 ng of RNA. Paired end sequence reads (75 bp in length) were generated on a NextSeq 500 (Illumina, San Diego, USA). The sequencing reads were processed to remove Illumina barcodes and aligned to the Ensemble Mus musculus reference genome (build GRCm38/B7) using STAR v.2.5.1b with default parameters (https://academic.oup.com/bioinformatics/article/29/11/1527537/login=false). Differential expression analysis was performed using the GLM approach implemented in the R/Bioconductor20 edgeR v3.24.3 package (FDR ≤ 0.05).21 Functional enrichment was performed with the function enrichPathway of clusterProfiler v3.10.1 R package (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393797/) against Reactome pathway database (P ≤ 0.01). Complete RNA-sequencing data set are available from the Gene Expression Omnibus (GEO) under the accession number GSE137669.

2.12 Carnitine acetyltransferase enzymatic activity
Carnitine acetyltransferase (CrAT) assay was performed as described22 Briefly, LVS were homogenated in T-PER buffer and diluted 1:10 in assay buffer (50 mM Tris-HCl, 1 M EDTA, 0.45 mM acetyl-CoA, 0.1 mM DTNB; pH = 7.8). After 2 min of baseline measurement, 5 mM L-carnitine was added, and CrAT enzymatic activity was assessed by measuring the rate of reduction of DTNB (412 nm) by the free CoA liberated from acetyl-CoA. Results were then normalized to total protein content.

2.13 Valine oxidation assay
Valine oxidation was assessed as reported.23 LVS (10–20 mg) were minced in 20 mM HEPES, 200 mM adenosine, 2% BSA (FA-free), 5 mM glucose, 1 mM Valine (non-radioisotope). Minced tissue was collected and placed in polypropylene tubes with 160 μCi/mmol [1-14C]valine (50 μCi: MORpure, Avantor, USA) and incubated 1 h at 37°C with shaking. Afterwards, hydrogen peroxide (final concentration 10%) was added and [14C] CO2 was trapped in filter paper soaked with 300 μL of 1 M benzenethionium hydroxide solution for 30 min at room temperature. Radioactivity was then counted by scintillation and data were normalized to mg of tissue.

2.14 In vitro model of cardiac hypertrophy and EAAm supplementation
HL-1 cardiomycocytes (Sigma-Aldrich—SCC065) were grown in a complete Claycomb medium supplemented with 10% fetal bovine serum (FBS), 0.1 mM norepinephrine, 100 U/ml penicillin/streptomycin, 2 mM L-glutamine in gelatin/fibronectin-coated flasks (all supplements from Sigma-Aldrich) at 37°C, 5% CO2. Although HL-1 cells are not ideal for studying cardiomycocytes metabolism, they are, however, widely used to study cardiomycocyte hypertrophy in vitro.24 Endothelin-1 (ET-1) (100 nM in DMSO) (Sigma-Aldrich) was added to cells (80–90% confluent) that were previously deprived for 48 hr of norepinephrine and then serum-starved overnight. For EAA supplementation, HL-1 cells were treated with vehicle or ET-1 as described above or supplemented with an essential amino acid mixture (EAAm) alone or in combination with ET-1 in Claycomb medium without FBS and norepinephrine. The mixture reproduces the stoichiometric ratio of the EAAm in the SFA-EAA defined diet, which, in turn, is based on the blend of AAs that has been previously shown, when supplemented with drinking water, to extend the average life span in mice.11 After 24 h, cells were harvested for analysis.

2.15 Statistical analysis
For each experiment sample size reflects the number of independent biological replicates and is provided in the figure legend. Sample size was determined on the basis of previous experience. Statistical analyses were performed using unpaired Student’s t-test for two group analysis or two-way ANOVA followed by post hoc Tukey’s test using Prism 6.0 software (GraphPad Software, Inc.). For metabolomics data, a two-way ANOVA followed by post hoc Tukey’s test using Prism 6.0 software (GraphPad Software, Inc.). For metabolomics data, a two-way ANOVA followed by post hoc Tukey’s test using Prism 6.0 software (GraphPad Software, Inc.).
3. Results

3.1 SFA-EAA diet prevents HFrEF
To test the effects of the SFA-EAA diet on heart function in response to pathological stress, we fed mice with the SFA or SFA-EAA diet for 10 days and then subjected them to TAC to induce LV pressure overload or sham surgery (Figure 1A). Following surgery, mice fed with the SFA-EAA diet for further 4 weeks showed attenuated features of HFrEF progression compared with mice fed with the SFA diet. In particular, cardiac enlargement, significant in TAC mice fed with SFA diet, was absent in TAC mice fed with the SFA-EAA diet: as a consequence, in this latter group, heart and LV weight were similar to those of sham controls when normalized to tibial length. (Figure 1B, Supplementary material online, Figure S1A), as well as normalized the increased ratio of lung weight/tibial length occurring in TAC animals fed with SFA diet (Figure 1C). An improvement in cardiac performance upon SFA-EAA feeding of TAC-operated mice was evident with transthoracic echocardiography, showing values of fractional shortening (FS), ejection fraction (EF), and left ventricular internal diameter end diastole (LVIDd) and left ventricular internal diameter end systole (LVIDs) comparable with those observed in sham-operated mice fed with SFA diet (Figure 1D and E, Supplementary material online, Figure S1B and Supplementary material online, Table S4). The improved cardiac phenotype of SFA-EAA-fed mice was accompanied by reduced LV interstitial fibrosis and cardiac stress markers compared to those fed with the SFA diet upon pressure overload (Figure 1F and H).\(^{26}\) Furthermore, the TAC-induced increase in cardiomyocytes cross-sectional area (CSA) of SFA-fed mice was also reduced by the SFA-EAA diet (Figure 1G).

To determine whether the preventive effect of the SFA-EAA diet was indeed due to its specific amino acid composition and not only to free amino acid substitution per se or dietary protein deprivation, we generated another engineered diet in which a mixture of free amino acids designed on the amino acid profile of casein replaced the protein component as in the SFA-EAA diet (we referred to this engineered diet as SFA-CAA; Supplementary material online, Table S1). Of note, there was no protective action on the cardiac function when mice fed with the SFA-CAA diet were TAC-operated (see Supplementary material online, Figure S2A–E and Supplementary material online, Table S5). Thus, we decided to compare the SFA-EAA diet to the SFA diet as control. Overall, these results indicate that our specific dietary intervention effectively prevents the development of LV hypertrophy upon pressure overload.

3.2 SFA-EAA diet ameliorates preestablished HFrEF
We next asked whether the SFA-EAA diet could block the progression of cardiac dysfunction in the preestablished HFrEF. Two weeks after surgery, when the cardiac function was significantly reduced in TAC- compared to sham-operated mice, the animals were randomized to receive either the control SFA or the SFA-EAA diet for six weeks (see Supplementary material online, Figure S3A). We found that the SFA-EAA diet significantly blocked HF progression; the ratio of heart weight/tibial length, which was increased in TAC-SFA animals, was reduced considerably by SFA-EAA feeding; furthermore, the TAC-SFA-induced augmented ratio of lung weight/tibial length, also tended to be blunted by SFA-EAA, albeit not significantly (see Supplementary material online, Figure S3B and C). Notably, SFA-EAA-fed mice did not display any further reduction in FS and EF, resulting in a considerably increased LV function by the end of the experiment compared with SFA-fed mice (see Supplementary material online, Figure S3D–F and Supplementary material online, Table S6). Moreover, cardiac stress markers’ expression was significantly induced in controls and greatly reduced by the SFA-EAA diet (see Supplementary material online, Figure S3C). Thus, the SFA-EAA diet consumption substantially benefits HF progression even when the disease is already established. Although we did not measure the survival rate in mice subjected to sham/TAC surgery before or after feeding SFA or SFA-EAA diet, our previous results\(^{12,26}\) together with recent data which show that both genetic and pharmacological stimulation of mitochondrial biogenesis/activity increased the survival of post-TAC mice,\(^{27}\) suggest that the substituted diet may extend survival after TAC; however, further experiments will investigate this critical topic.

3.3 Effects on the whole-body metabolism
Both mice fed with the SFA-EAA diet as in Figure 1A (i.e. preventive protocol) and Supplementary material online, Figure S3A (i.e. therapeutic protocol) showed a slight decrease in body weight compared to SFA-fed mice (see Supplementary material online, Figure S4A). Similarly, feeding the SFA-EAA diet increased whole-body glucose tolerance compared to the SFA diet in sham- and TAC-operated mice (see Supplementary material online, Figure S4B). Likewise, when mice were challenged with an insulin tolerance test, the hypoglycaemic effect of insulin was more pronounced in mice fed with the SFA-EAA diet compared with SFA-fed animals of both sham and TAC groups (see Supplementary material online, Figure S4C). These results align with those we previously described in not operated mice.\(^{28}\) To test whether the dietary manipulation affects cardiac insulin signalling, we determined insulin receptor substrate 1 (IRS1) and Akt activation as indicated by pan-tyrosine phosphorylation assay and serine 473 phosphorylation, respectively, eight weeks after sham and TAC in LV. The pan-tyrosine phosphorylation of IRS1 increased after TAC surgery relative to sham mice fed with the SFA diet, as previously described in Chow-fed animals\(^{28}\) (see Supplementary material online, Figure S4D). Notably, the SFA-EAA diet completely prevented this induction. We observed similar results with Akt (Ser473) phosphorylation normalized to total Akt (see Supplementary material online, Figure S4E). Further analysis showed that neither cardiac TAC surgery nor SFA or SFA-EAA diets affected insulin signalling in both muscle and liver, as indicated by unchanged IRS1 phosphorylation levels in those organs, thus confirming the tissue-specific effect of the SFA-EAA diet on blunting TAC-induced cardiac insulin signalling hyperactivation (see Supplementary material online, Figure S4F and G).

Thus, our results suggest that the pressure overload after TAC surgery activates markers of cardiac insulin signalling and that a specific EAA-substituted diet could prevent excessive activation of these markers.

3.4 The metabolic reprogramming induced by the SFA-EAA diet reinstates myocardial energy homeostasis in HFrEF
To clarify the impact of the SFA-EAA diet on systemic metabolism, we performed unbiased metabolic profiling of plasma from mice subjected to the preventive protocol. Principal component analysis (PCA) showed a clear separation of the two TAC groups as indicated by unchanged pan-tyrosine phosphorylation assay and serine 473 phosphorylation, respectively, eight weeks after sham and TAC in LV. The pan-tyrosine phosphorylation of IRS1 increased after TAC surgery relative to sham mice fed with the SFA diet, as previously described in Chow-fed animals\(^{28}\) (see Supplementary material online, Figure S4D). Notably, the SFA-EAA diet completely prevented this induction. We observed similar results with Akt (Ser473) phosphorylation normalized to total Akt (see Supplementary material online, Figure S4E). Further analysis showed that neither cardiac TAC surgery nor SFA or SFA-EAA diets affected insulin signalling in both muscle and liver, as indicated by unchanged IRS1 phosphorylation levels in those organs, thus confirming the tissue-specific effect of the SFA-EAA diet on blunting TAC-induced cardiac insulin signalling hyperactivation (see Supplementary material online, Figure S4F and G).

Thus, our results suggest that the pressure overload after TAC surgery activates markers of cardiac insulin signalling and that a specific EAA-substituted diet could prevent excessive activation of these markers.

metabolites (n=146 and 155 of 572) were significantly upregulated or downregulated in response to the SFA-EAA diet in sham- and TAC-operated mice, respectively (Figure 2C and D). These included amino acids and fatty acids in the sham group (Figure 2E) and amino acids, fatty acids, and carbohydrates in the TAC group (Figure 2F). Next, we examined the metabolic changes elicited by the previous exposure to different dietary interventions in TAC-operated mice on this subset of metabolites. While in SFA-fed mice, the TAC intervention induced changes in the levels of 206 metabolites in total (37% upregulated—mostly carbohydrates and amino acids—and 63% downregulated—mostly fatty acids) (Figure 3A and B), in SFA-EAA-fed animals, TAC changed the total levels of only 114 metabolites (23% upregulated—mainly fatty acids—and 77% downregulated—mainly fatty acids and amino acids) (Figure 3A–C). Notably, the SFA-EAA diet restored the levels of 88 and 69% metabolites, upregulated and downregulated, respectively, in the failing heart (Figure 3D). In mice fed with the SFA diet, TAC increased central metabolic pathways, including glycolysis, pentose phosphate pathway, and methionine metabolism (Figure 3E), which were all blunted by the SFA-EAA diet. In particular, the levels of the glycolytic intermediates fructose-6-phosphate, fructose-1,6-diphosphate, glucose-1-phosphate, glucose-6-phosphate, fructose 6-phosphate, pyruvate, and lactate, and those of pentose phosphate pathway metabolites sedoheptulose-7-phosphate, ribulose/xylulose-5-phosphate, and 6-phosphogluconate—markedly enriched in TAC-operated mice fed with SFA diet—were reduced to levels similar to those observed in control sham-operated mice fed with SFA diet (Figure 3F).

Additionally, the cardiac acylcarboxylic levels were significantly lower in TAC-operated mice fed with the SFA diet than in sham-operated mice fed with the SFA diet (see Supplementary material online, Figure S6). However, the SFA-EAA diet consumption blunted this effect reversing TAC-induced changes. Similarly, the SFA-EAA diet dampened the TAC-increased levels of polyamines, such as putrescine and spermidine—metabolites indicative of the fibrotic response, known to be associated with pressure overload cardiac dysfunction (Figure 3G).29,30 Together, these results suggest that the amino acid-substituted diet may promote a more energy-efficient oxidative metabolism in the failing heart. BCAA oxidation seems among the most prominently affected pathways (Figure 3H).

3.5 Transcriptomic reprogramming induced by the SFA-EAA diet

We next sought to determine how this cardiac metabolic shift affects heart function and explains the beneficial effects observed with the SFA-EAA diet. PCA analysis of cardiac transcriptome showed that the gene expression patterns in LV of sham-operated mice (preventive protocol as in Figure 1A) were mainly similar between diets. In contrast, in LV of TAC-operated animals, the patterns displayed extremely distinct profiles (Figure 4A). Notably, TAC mice fed with the SFA-EAA diet hierarchically clustered more closely with SFA- and SFA-EAA-fed sham mice than with the SFA-TAC mice (Figure 4B). Comparative analysis revealed that the SFA-EAA diet significantly regulated 94 genes in sham- and 305 genes in TAC-operated mice. Consistent with previous results, pressure overload extensively modulates gene expression in LV,11 remarkably, a total of 36% of these transcripts (n = 185 of 516) was entirely restored by the SFA-EAA diet (Figure 4C). The volcano plot demonstrated that feeding the SFA-EAA diet strongly damped multiple TAC-upregulated stress genes (e.g. Myh7, Acta1, Nppa, and Ctgf) (Figure 4D, left panel). Similarly, numerous TAC-downregulated genes were recovered by the SFA-EAA, including those related to carbohydrate metabolism, tricarboxylic acid (TCA) cycle, and BCAA catabolism (Figure 4D, right panel). According to the pathway analysis of genes rescued by the SFA-EAA diet, several processes implicated in HF pathophysiology were identified, including glucose metabolism, extracellular matrix organization, immune system response, and membrane potential regulation (Figure 4E).

Thus, the SFA-EAA diet in TAC mice appears to induce a transcriptional cardiac response with a pattern opposite to that of pressure overload, which involves the expression of stress and metabolic genes known to play a critical role in the failing heart.

3.6 Mitochondrial respiration and BCAA oxidation

Joint pathway analysis of transcriptomics and metabolomics data with Integrated Molecular Pathway Level Analysis (IMpALA)32 revealed respiratory electron transport chain (ETC), TCA cycle, and BCAA oxidation as the most coherent pathways (Figure 4F). Of note, the SFA-EAA diet restored both BCAA catabolite levels (Figure 4G) and expression of BCAA oxidation genes (Figure 4H), which were upregulated and downregulated, respectively, in LV of mice underwent TAC surgery. In addition, the SFA-EAA diet rescued mRNA levels of the peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) and transcription factor A (Tfam) (mitochondrial biogenesis regulators), cytochrome c oxidase subunit IV (COX IV) and cytochrome c (Cyt c) (mitochondrial respiratory ETC), and optic atrophy 1 (OPA1) (inner mitochondrial membrane, which regulates mitochondrial fusion and cristae structure), as well as mitochondrial DNA (mtDNA) amounts, in LV of TAC mice (see Supplementary material online, Figure S7A and B).

On the other hand, CrAT activity—which regulates substrate oxidation in mitochondria and cardiac metabolic flexibility—was decreased in TAC mice fed with the SFA diet and restored to control levels by the SFA-EAA diet (Figure 5A). Impaired CrAT activity leads to hyperacetylation of mitochondrial proteins leading to mitochondrial dysfunction,34 furthermore, mitochondrial protein lysine hyperacetylation is observed in the early stages of HF.35 We thus measured mitochondrial lysine acetylation in cardiac tissue of TAC-operated mice. Compared with sham mice, TAC increased acetyl-lysine (AcK) residues in SFA but only partially in SFA-EAA-fed animals (Figure 5B), further supporting the beneficial effect of the substituted diet on mitochondrial function.

To test this event directly, we assessed respiration in isolated cardiac mitochondria. Pressure overload considerably reduced basal and maximal oxygen consumption of mitochondria isolated from LV of mice fed with the SFA diet (Figure 5C). On the contrary, the SFA-EAA diet completely restored basal and maximal respiration in TAC-operated mice without changing oxygen consumption in the sham-operated animals (Figure 5G). Of note, this effect was observed only with pyruvate but not with palmitoyl-carnitine-driven mitochondrial respiration, suggesting a selective restoration of mitochondrial glucose oxidation (see Supplementary material online, Figure 5C). Ultrastructure analysis also revealed that the SFA-EAA diet corrected mitochondrial damage in the LV cardiomycocytes of TAC-operated mice. While in the SFA-TAC mice, the cardiac mitochondria were numerous, enlarged, spherical, with the sign of fission—as widely reported in the literature,35 their appearance in the SFA-EAA-TAC mice was comparable to SFA-sham mice, with a more heterogeneous and elongated morphology (Figure 5D). Of note, LV transverse sections showed a massive accumulation of amorphous material—damaged sarcemtic myofilaments and other constituents—and Z-lines completely deranged in SFA-TAC mice (see Supplementary material online, Figure 5D). These damage signs were absent in TAC-operated mice fed with the SFA-EAA diet (see Supplementary material online, Figure 5D).

To investigate further the mechanism underlying the regulation of mitochondrial substrate utilization by the substituted diet, we established an in vitro model of cardiomyocyte hypertrophy in which endothelin-1 (ET-1) hypertrophic HL-1 cardiomycocytes were supplemented with an EAA-enriched mixture (EAAm) stoichiometrically equivalent to the amino acid content of the SFA-EAA diet. As shown in Supplementary material online, Figure 5E), ET-1 increased the expression of Nppa and Nppb, which were reduced to control levels by EAAm. Besides confirming the efficacy of the in vitro model, these data also suggest a cell-autonomous mechanism of action of the designer diet. Furthermore, in line with the results on
Dietary amino acids and heart failure

mitochondrial biogenesis markers, while ET-1 downregulated COX IV protein expression, EAAm restored it (see Supplementary material online, Figure S7F). Most importantly, EAAm supplementation normalized the ET-1-induced increase in Ser293-phosphorylation of the α1 subunit of pyruvate dehydrogenase complex (PDH) in HL-1 cardiomyocytes, thus confirming, accordingly with the OCR data (Figure 5C), the ability of the EAAm to reduce the impairment in pyruvate oxidation and therefore to improve metabolic flexibility in mitochondria of hypertrophic cardiomyocytes (see Supplementary material online, Figure S7F). However, the pyruvate dehydrogenase kinase 4 (PDK4) mRNA levels were unchanged by ET-1 and EAAm (data not shown), thus suggesting that in our *in vitro* model, the regulation of PDH activity could proceed through a mechanism independent of PDK4 transcription.

The entire catabolic pathway of BCAAs is located in mitochondria. Unexpectedly, given the high content of BCAAs, but consistent with the increased mitochondrial function, the SFA-EAA diet renormalized increased BCAA levels in LV of TAC-operated mice (Figure 4G). It also restored the cardiac levels of many BCAA oxidation products and BCAA oxidative enzymes in the failing heart (Figure 4G and H). Accordingly, valine oxidation was decreased by pressure overload in SFA-fed mice and...
recovered by the SFA-EAA diet (Figure 6). Beyond normalizing the TAC-induced BCAA and their catabolite accumulation in cardiac tissue (Figure 4G), the substituted diet restored glucose oxidation, which is impaired in the failing heart (Figures 3F, 5C). Given that high BCAA level inhibits glucose metabolism and, in reverse, glucose promotes cell growth by suppressing BCAA degradation,38 we hypothesized that the SFA-EAA diet could reduce the TAC-induced activation of the mechanistic target of rapamycin (mTOR) kinase. The BCAA leucine promotes activation of mTOR, which stimulates protein synthesis—leading to development of pathological hypertrophy of adult hearts in vivo.38 Phosphorylation of eukaryotic translation initiation factor 4E (eIF4E)-binding protein (4E-BP1) and S6 ribosomal protein (S6), two mTOR complex 1 (mTORC1) downstream targets, was lower in TAC-operated mice fed with SFA-EAA than SFA diet (see Supplementary material online, Figure S8). Together, these results—line with previous findings39–41—strongly indicate that a reduced BCAA catabolism promotes BCAA accumulation, mTOR activation, and cardiac hypertrophy in TAC mice. Moreover, our results suggest that the SFA-EAA-activated mitochondrial biogenesis and function could reduce the cardiac BCAA levels, mTOR activity, and dysfunction.

3.7 The beneficial effects of the SFA-EAA diet in HFrEF require protein phosphatase PP2Cm

BCAAs are reversibly converted by mitochondrial branched-chain aminotransferase (BCAT2) into branched-chain α-keto acids, which are irreversibly decarboxylated by the branched-chain α-ketoacid dehydrogenase (BCKDH) complex and other enzymes into TCA cycle intermediates.42 The BCKDH complex is inactive when phosphorylated by branched-chain α-keto acid dehydrogenase kinase (BCKDK) and active when dephosphorylated by 2C-type serine-threonine protein phosphatase (PP2Cm, encoded by Ppm1k) (Figure 7A).16,43 We confirmed a reduced expression of these critical BCAA catabolic enzymes (except for BCKD kinase) in the failing heart of SFA-fed mice (Figure 7B and C). However, we observed a coordinated increase of the same set of proteins in TAC mice fed with the SFA-EAA diet (Figure 7B and C). In contrast, no significant modification of their expression was evident in white adipose tissue (except for BCAT2), liver (except for BCAT2 and PP2Cm), and skeletal muscle of sham- and TAC-operated mice on the various dietary regimens (see Supplementary material online, Figure S9A–C).

Figure 3 SFA-EAA diet preserves cardiac metabolism upon pressure overload. (A) Bars represent the number of metabolites significantly upregulated or downregulated (P ≤ 0.05) by TAC in LV of mice fed with SFA and SFA-EAA diet as in Figure 1A (n = 6 mice per group). (B and C) Biochemical classification of metabolites in LV of TAC-operated mice, shown as the number of metabolites for each class significantly modulated by SFA (B) and SFA-EAA diet (C) (n = 6 mice per group). (D) Percentage of metabolites in LV of SFA-fed mice, upregulated (left) or downregulated (right) by the pressure overload and that were rescued or not by the SFA-EAA diet (n = 6 mice per group). (E) Pathway-enrichment analysis of metabolites significantly (P ≤ 0.05) increased upon TAC in the SFA group (n = 6 mice per group). (F) Heatmap of cardiac metabolites showing the levels (red = high, blue = low) of differentially regulated intermediates involved in glycolytic, gluconeogenesis, and pentose phosphate pathway in sham- and TAC-operated mice fed with SFA and SFA-EAA diet (n = 6 mice per group). (G) Polyamine metabolite levels in LV of sham- and TAC-operated mice fed with SFA and SFA-EAA diet. The relative scale intensity was determined by rescaling each metabolite (n = 6) to set the median equal to 1.0. All data are presented as mean ± SEM. ***P < 0.001 vs. sham-operated mice fed with SFA diet; #P < 0.05, ##P < 0.01, and ###P < 0.001 vs. TAC-operated mice fed with SFA diet. Statistical analysis was performed with two-way ANOVA followed by Tukey’s post hoc test (panel G) and Fisher’s Exact Test (E). (H) Schematic diagram showing the main metabolic pathways affected by the SFA-EAA diet in cardiac tissue of TAC-operated mice. Diagram was created with BioRender.com.

M. Ragni et al.
In cardiac tissue, these genes are regulated by the circadian gene Krüppel-like factor 15 (KLF15), which governs the transcriptional regulation of cell proliferation, differentiation, and metabolism; the expression of KLF15 is downregulated in failing hearts.

We confirmed that KLF15 was strongly downregulated following TAC in LV—but not in adipose, liver, and muscle (see Supplementary material online Supplementary material online, Figure S9)—of mice fed with the SFA diet; in contrast, its cardiac expression was significantly increased by the SFA-EAA diet (Figure 7B). Thus, to assess the involvement of BCAA catabolic pathway in the cardioprotective effects of the SFA-EAA diet, we used a mouse model carrying the genetic inactivation of Pbm1k (PP2Cm-KO), which lacks the activating phosphatase activity of PP2Cm on the key catabolic BCAA enzyme BCKDHA dehydrogenase. As a result, in PP2Cm-null mice, the subunit E1 of BCKDHA is hyperphosphorylated and inactive in response to

Figure 4 SFA-EAA diet preserves cardiac transcriptomic profile upon pressure overload. (A) Three-dimension principal component analysis (3D PCA) of RNA-seq data in LV samples obtained from sham- and TAC-operated mice fed with SFA or SFA-EAA diet as reported in Figure 1A. (B) Heatmaps of cardiac transcripts showing the levels (red = high, blue = low) of differentially regulated genes following sham and TAC surgery in mice on the different dietary regimens. Statistical criteria is false discovery rate (FDR < 0.05) (n = 2 mice per group). The upregulated (dark red), downregulated (dark blue), or not changed (grey) gene groups are also reported in TAC-operated mice fed with SFA-EAA vs. SFA diet or in TAC- vs. sham-operated mice fed with SFA diet (the two left columns). (C) Venn diagram showing upregulated (red circle) and downregulated (blue circle) genes in LV following pressure overload, and the genes entirely restored by the SFA-EAA diet (overlap). (D) Volcano plot showing cardiac genes upregulated (red in the left panel) and downregulated (red in the right panel) by TAC surgery and their restoration by the SFA-EAA diet (blue in the left and right panels, respectively) (n = 2 mice per group; FDR < 0.05). (E) Pathway analysis of cardiac genes significantly modulated by the SFA-EAA diet in TAC-operated mice. The P-values indicate the enrichment level of the pathway term; the colour intensity and size indicate the significativity level and the number of proteins included in a single pathway, respectively. (F) Joint pathway analysis of transcriptomics and metabolomics data (n = 6 mice per group). (G) Heatmap of the levels of BCAA catabolites in sham- and TAC-operated mice fed with SFA or SFA-EAA diet (n = 6 mice per group). (H) Heatmap of the expression profile of BCAA oxidation genes in mice fed with SFA or SFA-EAA diet and subjected to sham or TAC surgery. Differential expression analysis was performed using the GLM approach in edgeR using a false discovery rate (FDR), while pathway analysis was made with Integrated Molecular Pathway Level Analysis (IMPaLA) using a P-value from Fisher’s Exact Test.
We reasoned that if the BCAA catabolic pathway is required for the cardioprotective effect of the SFA-EAA diet in TAC mice, then the SFA-EAA-fed PP2Cm-null animals, in which the BCAA catabolism is impaired, should not show any improvement in cardiac function after TAC. The decrease in heart functional outcomes in these null mice—more evident following TAC than in wild-type mice—was resistant to the beneficial effects of the SFA-EAA diet under the therapeutic protocol (Figure 7D–G and Supplementary material online, Table S7). Notably, the cardioprotective benefits were absent even if the SFA-EAA diet reduced body weight (Figure 7H) and ameliorated whole-body insulin sensitivity in TAC-operated mice compared with the SFA diet. Statistical analysis was performed using two-way ANOVA followed by the Tukey’s post hoc test.

**4. Discussion**

Current therapies for cardiac hypertrophy and HF are primarily based on pharmacological and surgical approaches mainly for relieving ventricular haemodynamic stress, controlling symptoms, and increasing exercise capacity. However, alteration of metabolic substrate utilization in myocardial tissue is a major hallmark in hypertrophy and HF; reduced metabolic flexibility—that is, the inability to adapt to altered metabolic fuel supplies during diverse physiological and pathophysiological conditions—underlies the majority of morphological and biochemical adaptations which take place in these pathological conditions. Therefore, reinstating the compromised metabolic homeostasis and imbalance of substrate utilization is a valuable therapeutic target in failing heart. In this context, dietary manipulation is widely accepted as a beneficial approach to HF; however, most studies obtained unsatisfactory results to progress towards better evidence-based nutritional advice for patients. For instance, adherence to the Mediterranean diet or dietary approaches to stop hypertension (DASH), typically low in saturated fat and high in complex carbohydrates, fish, and vegetables, was associated with improved systolic and diastolic function in individuals with HFpEF and HFrEF. However, their benefits are to be confirmed in large randomized trials. Alternatively, high-fat, low-carbohydrate ketogenic diets have been found to improve cardiac function.
Mechanistically, the cardioprotective impact of the SFA-EAA diet appears to be mediated through mutually nonexclusive effects on systemic metabolism and local cardiomyocyte signaling. Lower body weight and an improved hypoglycaemic response to insulin might explain the protective and therapeutic effects of the SFA-EAA diet when fed to TAC mice. However, this diet prevents body weight gain also in PP2Cm deficient mice without ameliorating their cardiac performance when exposed to pressure overload. Interestingly, PP2Cm deficient mice have lower body weight and higher insulin sensitivity than wild-type mice but show a more severe deterioration of heart function than controls when exposed to TAC surgery. Overall, these results, together with the in vitro results, seem thus to limit the relevance of actions on systemic metabolism in explaining the advantages of the SFA-EAA diet in the failing heart. Notably, the plasma and cardiac levels of BCKA catabolites were upregulated in TAC-operated mice fed with the SFA-EAA diet (see Supplementary material online, Figure S5D), and this matched with reduction of the LV levels of BCKAs, which are toxic metabolites in cardiac tissue.

On the other hand, insulin receptor (IR) signalling is activated in hypertrophic cardiac tissue of TAC mice fed with the SFA diet, and IRS1 seems to be involved, as indicated by increased phosphorylation of IRS1 and Akt signalling proteins. These findings confirm those previously reported by Riehle et al. in LV of TAC-operated mice. However, our observation that the SFA-EAA diet fully antagonized the activated IR signalling in TAC mice seems relevant, particularly in the suggested synergism between the increased IR activation and the stretch-mediated activation of IRS1/Akt/mTOR signalling pathways leading to hypertrophy in failing heart. An earlier study demonstrated that reducing insulin signalling by lowering circulating insulin or IR or Akt expression attenuated the onset of HF.

The SFA-EAA-induced metabolic and transcription reprogramming reinstates myocardial energy supplies in HFrEF. While plasma and cardiac metabolite clusters following TAC surgery in SFA-fed mice suggest the involvement of multiple biochemical networks widely known in the pathophysiology of failing heart—including impaired glucose, fatty acid, and amino acid oxidation, with increased glycolysis and pentose phosphate pathway—in mice fed with the SFA-EAA diet these clusters are more similar to those observed in the SFA-fed animals after sham surgery. We speculate that the HFrEF-related alteration of the glucose, fat, and amino acid metabolism might be a consequence of the decline of mitochondrial oxidative function or an increased mitochondrial function demand, rather than the reduced activity of single biochemical circuitry and that the global metabolic reprogramming induced by our substituted diet might be linked to a direct action on mitochondria. We have previously shown that the SFA-EAA diet is a potent inducer of mitochondrial biogenesis and function under diverse experimental conditions. Our present results also support this possibility, showing that the TAC-induced decline of expression of PGC-1α and OPA-1, among other genes promoting mitochondrial biogenesis and function, is rescued by the SFA-EAA diet. Also, we observed a significant reduction of lysine acetylation of mitochondrial proteins—due to restoration of CrAT activity—and a consequent improvement of mitochondrial function in SFA-EAA-fed TAC mice compared with SFA-fed TAC animals. Notably, CrAT null mice show impaired mitochondrial pyruvate oxidation, glucose sensitivity, and metabolic flexibility, with hyperacetylation and dysfunction of mitochondrial proteins. The SFA-EAA diet restored the defective pyruvate/malate-dependent mitochondrial respiration in TAC-operated mice, suggesting the restoration of the mitochondrial glucose oxidation capacity. Thus, one can hypothesize that the ability of the SFA-EAA diet to stimulate CrAT activity might explain the improved glucose oxidation and balance in metabolic substrate utilization of the failing heart. However, because the substrate fluxes do not strongly correlate with both mRNA levels of metabolic enzymes and mitochondrial respiration, our hypothesis will need to be adequately tested in future studies using in vivo substrate and glucose flux measurements. Nevertheless, one should note that our metabolomic and transcriptomic results agree with previous investigations describing the
metabolic flux analysis in mice subjected to pressure overload. Moreover, our dietary manipulation could affect systemic or coronary vascular resistance, which may alter metabolic flux, and this will have to be assessed adequately.

Showing the SFA-EAA diet improves glucose oxidation is relevant because high glucose is known to cause the hypertrophic growth of the heart under stress conditions, which ultimately leads to HF. Shao et al. suggests that increased intracellular glucose transcriptionally suppresses KLF15 and its downstream genes, resulting in a decreased BCAA degradation. Such a process leads to the accumulation of intracellular BCAA that coincides with mTOR activation. Several observations have been made that KLF15 and BCAA degradation enzymes’ expression is downregulated in failing hearts. Our findings suggest that the beneficial anti-hypertrophic effects of the SFA-EAA diet in the overload pressure model of HFrEF may be explained partly by modulation of the KLF15-BCAA-mTOR pathway. In particular: (i) the TAC-induced reduction of cardiac KLF15 expression in sham-operated mice is restored to control values in the SFA-EAA-fed animals; (ii) similar results are observed for the expression of multiple genes of amino acid metabolism, including PP2Cm, with (iii) an apparent normalization of BCAA oxidation in cardiac tissue of the TAC-operated mice fed with the SFA-EAA diet; and finally (iv) the TAC-induced mTOR activation is fully inhibited by the SFA-EAA consumption, mimicking the beneficial effects of mTOR inhibitor rapamycin on cardiac hypertrophy. Consistently, the substituted diet reduces IR-mTOR-dependent hypertrophic signalling.

Some reports showed therapeutic efficacy of targeting BCAA catabolic flux in TAC-induced HF with BT2 (3,6-dichlorobenzothiophene-2-
carboxylic acid), a small-molecule inhibitor of BCKDK used to enhance BCAA catabolism. The BT2-treated mice showed significantly preserved cardiac function and structure after TAC, with improved systolic contractility and diastolic mechanics. These therapeutic benefits appeared independent of impacts on LV hypertrophy, suggesting that our SFA-EAA diet may affect additional mechanisms and engage other EAA catabolic pathways, especially whether a marked reduction of protein content and substitution with a specific EAA mixture described in the present paper is therapeutically effective in humans with HF.\textsuperscript{71,72}

A few small clinical trials have evaluated the cardiac effects of EAA dietary supplements in patients with HF\textsuperscript{ef}.\textsuperscript{73} With encouraging results on ventricular function and exercise tolerance. It remains to investigate whether a marked reduction of protein content and substitution with a specific EAA mixture described in the present paper is therapeutically effective in humans with HF.\textsuperscript{71,72}

5. Conclusion
In summary, the present study indicates that a specific manipulation of dietary amino acids prevents and reverses HF\textsuperscript{ef} in mice through multiple modes. If extended to humans, such dietary manipulation could potentially impact cardiac and systemic metabolic health, favouring the prevention and treatment of HF regardless of calorie consumption.

Author contributions

Supplementary material
Supplementary material is available at Cardiovascular Research online.

Acknowledgements
The authors thank R. Aquilani (Department of Biology and Biotechnology ‘Lazzaro Spallanzani’, University of Pavia, Pavia, Italy) for discussion.

Conflict of interest: None declared.

Funding
This work was supported by the European Research Council Advanced Grant (CardioEpigen, # 294609), Cariplo Foundation (grant # 2015583WMX) to G.C., Professional Dietsetic (Milan, Italy) and Fondazione Cariplo (grant no. 2016-1006) to E.N. C.R. was supported by Fondazione Umberto Veronesi.

Data availability
RNA-seq data is available in GEO under the accession number GSE137669. The data underlying this article are available in the article and in its online supplementary material.

References
4. Gheorghe M, D’Amico G, D’Alessio A, D’Antona G, Ragni M, Cardile A, Tedesco L, Dossena M, Bruttini F, Caliaro F, Condorelli G, Coppari R, Collins S, Valerio A, Nisoli E. Manipulation of dietary amino acids prevents and reverses HFrEF in mice through multiple catabolic mechanisms and engage other EAA catabolic pathways, especially whether a marked reduction of protein content and substitution with a specific EAA mixture described in the present paper is therapeutically effective in humans with HF.\textsuperscript{71,72}
17. Fontaine DA, Davis DB. Attention to background strain is essential for metabolic research: C57BL/6 and the international knockout mouse consortium. Diabetes 2016;65:25–33.
prevents and reverses obesity in mice through multiple mechanisms that modulate energy homeostasis. Diabetes 2020;69:2234–2339.
**Translational perspective**

Recent studies have identified the critical role of amino acid metabolism perturbation in the pathogenesis of heart failure with reduced ejection fraction. The consumption of a designer diet, in which a specifically formulated free essential amino acid mixture substitutes for proteins, improves branched-chain amino acid oxidation and attenuates systolic dysfunction in transverse aortic constriction-induced left ventricle pressure overload in mice. In addition, the substituted diet increases energy metabolism, promoting myocardial bioenergetics, efficient substrate utilization, and reduces fibrosis. The dietary modulation of energy production and amino acid metabolism represents a novel therapeutic paradigm to prevent or treat cardiac dysfunction, a promising supportive approach for treating cardiac diseases with depressed cardiac ejection fraction.